AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS: AXIM · Delayed Price · USD
0.0123
+0.0020 (18.93%)
Apr 25, 2024, 3:59 PM EDT - Market closed
Company Description
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases.
The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests.
It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.
The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.
AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
AXIM Biotechnologies, Inc.
| Country | Canada |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | John W. Huemoeller II |
Contact Details
Address: 6191 Cornerstone Court, E, Suite 114 San Diego, California 92121 United States | |
| Phone | (212) 751-0001 |
| Website | aximbiotech.com |
Stock Details
| Ticker Symbol | AXIM |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001514946 |
| CUSIP Number | 05463V100 |
| ISIN Number | US05463V1008 |
| Employer ID | 27-4092986 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John W. Huemoeller II | President, Chief Executive Officer and Director |
| Robert T. Malasek | Chief Financial Officer and Secretary |
| Catalina Valencia J.D. | Co-Founder and Chief Executive Officer of Sapphire Biotech, Inc. |
| Kurt Phinney | Chief Operating Officer |
| Dr. Sergei A. Svarovsky M.B.A., Ph.D. | Chief Scientific Officer and Co-Founder of Sapphire Biotech, Inc. |
| Dr. Alim Seit-Nebi Ph.D. | Chief Technology Officer and Co-Founder of Sapphire Biotech, Inc. |
| Jeffrey A. Busby | Senior Vice President of Business Development |
| Dr. Joseph Tauber M.D. | Chief Medical Officer and Chairman of the Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 21, 2024 | 8-K | Current Report |
| Feb 13, 2024 | 8-K | Current Report |
| Dec 28, 2023 | 8-K | Current Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Sep 21, 2023 | DEF 14C | Filing |
| Aug 31, 2023 | PRE 14C | Filing |
| Aug 21, 2023 | 10-Q | Quarterly Report |